BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34587961)

  • 61. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.
    Overgaard M; Jensen MB; Overgaard J; Hansen PS; Rose C; Andersson M; Kamby C; Kjaer M; Gadeberg CC; Rasmussen BB; Blichert-Toft M; Mouridsen HT
    Lancet; 1999 May; 353(9165):1641-8. PubMed ID: 10335782
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
    Habel LA; Shak S; Jacobs MK; Capra A; Alexander C; Pho M; Baker J; Walker M; Watson D; Hackett J; Blick NT; Greenberg D; Fehrenbacher L; Langholz B; Quesenberry CP
    Breast Cancer Res; 2006; 8(3):R25. PubMed ID: 16737553
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
    ; Forbes JF; Cuzick J; Buzdar A; Howell A; Tobias JS; Baum M
    Lancet Oncol; 2008 Jan; 9(1):45-53. PubMed ID: 18083636
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
    J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
    Love RR; Van Dinh N; Quy TT; Linh ND; Tung ND; Shen TZ; Hade EM; Young GS; Jarjoura D
    J Clin Oncol; 2008 Jan; 26(2):253-7. PubMed ID: 18086800
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tamoxifen for early breast cancer.
    Early Breast Cancer Trialists' Collaborative Group
    Cochrane Database Syst Rev; 2001; (1):CD000486. PubMed ID: 11279694
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
    Mansell J; Monypenny IJ; Skene AI; Abram P; Carpenter R; Gattuso JM; Wilson CR; Angerson WJ; Doughty JC
    Breast Cancer Res Treat; 2009 Sep; 117(1):91-8. PubMed ID: 19112615
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
    Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ;
    Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Breast Cancer Outcomes After Diagnosis of Hormone-positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era.
    Nye L; Rademaker A; Gradishar WJ
    Clin Breast Cancer; 2017 Jul; 17(4):e185-e189. PubMed ID: 28185739
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Predictors of time to death after distant recurrence in breast cancer patients.
    Sopik V; Sun P; Narod SA
    Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study.
    Guha N; Kwan ML; Quesenberry CP; Weltzien EK; Castillo AL; Caan BJ
    Breast Cancer Res Treat; 2009 Nov; 118(2):395-405. PubMed ID: 19221874
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical outcomes of female breast cancer according to BRCA mutation status.
    Cronin-Fenton DP; Kjærsgaard A; Nørgaard M; Pedersen IS; Thomassen M; Kaye JA; Gutierrez L; Telford C; Lewis J; Tyczynski JE; Sørensen HT
    Cancer Epidemiol; 2017 Aug; 49():128-137. PubMed ID: 28601786
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial.
    Zhang X; Gunda A; Kranenbarg EM; Liefers GJ; Savitha BA; Shrivastava P; Serkad CPVK; Kaur T; Eshwaraiah MS; Tollenaar RAEM; van de Velde CJH; Seynaeve CMJ; Bakre M; Kuppen PJK
    Breast Cancer Res; 2023 Apr; 25(1):40. PubMed ID: 37060036
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer.
    Li CI; Malone KE; Weiss NS; Daling JR
    J Natl Cancer Inst; 2001 Jul; 93(13):1008-13. PubMed ID: 11438566
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
    Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
    Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study.
    McCowan C; Wang S; Thompson AM; Makubate B; Petrie DJ
    Br J Cancer; 2013 Sep; 109(5):1172-80. PubMed ID: 23949153
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Analysis of Predictors of Breast Cancer Screening among Japanese Women using Nationally Representative Survey Data, 2001-2013.
    Okui T
    Asian Pac J Cancer Prev; 2021 Jan; 22(1):171-178. PubMed ID: 33507696
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
    Jakesz R; Hausmaninger H; Haider K; Kubista E; Samonigg H; Gnant M; Manfreda D; Tschurtschenthaler G; Kolb R; Stierer M; Fridrik M; Mlineritsch B; Steindorfer P; Mittlböck M; Steger G
    J Clin Oncol; 1999 Jun; 17(6):1701-9. PubMed ID: 10561206
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The relation between socioeconomic and demographic factors and tumour stage in women diagnosed with breast cancer in Denmark, 1983-1999.
    Dalton SO; Düring M; Ross L; Carlsen K; Mortensen PB; Lynch J; Johansen C
    Br J Cancer; 2006 Sep; 95(5):653-9. PubMed ID: 16909141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.